Vanda Pharmaceuticals
VNDA
S$6.03
Share price
-0.43%
Change (1 day)
-25.16%
Change (1 year)
Categories
Vanda Pharmaceuticals (VNDA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : S$0.15 Billion
According to Vanda Pharmaceuticals's latest financial reports the company's total liabilities are S$0.15 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Vanda Pharmaceuticals - Total liabilities on balance sheet (from 2005 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | S$0.15 B | 16.97% |
| 2023-12-31 | S$0.13 B | -4.72% |
| 2022-12-31 | S$0.14 B | 19.46% |
| 2021-12-31 | S$0.12 B | 13.24% |
| 2020-12-31 | S$0.10 B | 8.08% |
| 2019-12-31 | S$98.15 M | 26.69% |
| 2018-12-31 | S$77.47 M | -21.77% |
| 2017-12-31 | S$99.02 M | -13.44% |
| 2016-12-31 | S$0.11 B | 1.06% |
| 2015-12-31 | S$0.11 B | 686.87% |
| 2014-12-31 | S$14.38 M | -88.56% |
| 2013-12-31 | S$0.12 B | -18.11% |
| 2012-12-31 | S$0.15 B | -20.51% |
| 2011-12-31 | S$0.19 B | -14.5% |
| 2010-12-31 | S$0.22 B | -20.61% |
| 2009-12-31 | S$0.28 B | 4984.1% |
| 2008-12-31 | S$5.59 M | -70.38% |
| 2007-12-31 | S$18.89 M | 29.67% |
| 2006-12-31 | S$14.57 M | 72.02% |
| 2005-12-31 | S$8.47 M | 187.11% |
| 2004-12-31 | S$2.95 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | S$79.17 B | 50,920.17% | 🇨🇭 Switzerland |
 Eli Lilly LLY | S$94.68 B | 60,921.08% | 🇺🇸 USA |
 Johnson & Johnson JNJ | S$148.79 B | 95,786.96% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | S$96.53 B | 62,113.43% | 🇺🇸 USA |
 Pfizer PFE | S$151.14 B | 97,304.56% | 🇺🇸 USA |
 Titan Pharmaceuticals
TTNP | S$0.35 M | -99.77% | 🇺🇸 USA |
 Merck MRK | S$85.90 B | 55,262.23% | 🇺🇸 USA |